ENARABIO.COM: Keyword Density Checker

Total words: 1191 | 2-word phrases: 316 | 3-word phrases: 337 | 4-word phrases: 339

PAGE INFO

Title	Try to keep the title under 60 characters (74 characters) Advancing cancer immunotherapy by targeting the unconventional - Enara Bio
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (59 characters) Unleashing unconventional antigens for cancer immunotherapy

#	Keyword	Frequency	Density
1	enara bio	10	3.16%
2	dark antigen	4	1.27%
3	to develop	3	0.95%
4	dark antigens	3	0.95%
5	boehringer ingelheim	2	0.63%
6	genomic dark	2	0.63%
7	to host	2	0.63%
8	host 2nd	2	0.63%
9	2nd annual	2	0.63%
10	annual dark	2	0.63%
11	dark genome	2	0.63%
12	genome symposium	2	0.63%
13	and the	2	0.63%
14	develop offtheshelf	2	0.63%
15	offtheshelf immunotherapies	2	0.63%
16	bio to	2	0.63%
17	from enara	2	0.63%
18	antigens® from	2	0.63%
19	dark antigens®	2	0.63%
20	of cancer	2	0.63%

#	Keyword	Frequency	Density
1	host 2nd annual	2	0.59%
2	for nonsmall cell	2	0.59%
3	to host 2nd	2	0.59%
4	develop offtheshelf immunotherapies	2	0.59%
5	to develop offtheshelf	2	0.59%
6	boehringer ingelheim licenses	2	0.59%
7	ingelheim licenses multiple	2	0.59%
8	and nucleome therapeutics	2	0.59%
9	therapeutics and nucleome	2	0.59%
10	dark antigens® from	2	0.59%
11	antigens® from enara	2	0.59%
12	2nd annual dark	2	0.59%
13	rome therapeutics and	2	0.59%
14	bio to develop	2	0.59%
15	nonsmall cell lung	2	0.59%
16	about about enara	1	0.30%
17	enara bio to	1	0.30%
18	multiple dark antigens®	1	0.30%
19	licenses multiple dark	1	0.30%
20	news boehringer ingelheim	1	0.30%
21	story poster latest	1	0.30%
22	our story poster	1	0.30%
23	from enara bio	1	0.30%
24	immunotherapies for nonsmall	1	0.30%
25	offtheshelf immunotherapies for	1	0.30%
26	enara bio our	1	0.30%
27	cell lung cancer	1	0.30%
28	lung cancer nsclc	1	0.30%
29	cancer nsclc 4th	1	0.30%
30	nsclc 4th january	1	0.30%

#	Keyword	Frequency	Density
1	for nonsmall cell lung	2	0.59%
2	therapeutics and nucleome therapeutics	2	0.59%
3	rome therapeutics and nucleome	2	0.59%
4	boehringer ingelheim licenses multiple	2	0.59%
5	bio to develop offtheshelf	2	0.59%
6	to host 2nd annual	2	0.59%
7	host 2nd annual dark	2	0.59%
8	dark antigens® from enara	2	0.59%
9	to develop offtheshelf immunotherapies	2	0.59%
10	by our shared values	1	0.29%
11	shared values the culture	1	0.29%
12	our shared values the	1	0.29%
13	about about enara bio	1	0.29%
14	united by our shared	1	0.29%
15	and united by our	1	0.29%
16	purpose and united by	1	0.29%
17	representatives and investors to	1	0.29%
18	and investors to share	1	0.29%
19	about enara bio leadership	1	0.29%
20	values the culture we	1	0.29%
21	enables each of us	1	0.29%
22	the culture we have	1	0.29%
23	culture we have developed	1	0.29%
24	team driven by a	1	0.29%
25	each of us to	1	0.29%
26	of us to make	1	0.29%
27	us to make an	1	0.29%
28	to make an impact	1	0.29%
29	make an impact and	1	0.29%
30	an impact and deliver	1	0.29%
31	impact and deliver on	1	0.29%
32	and deliver on our	1	0.29%
33	deliver on our vision	1	0.29%
34	on our vision find	1	0.29%
35	driven by a common	1	0.29%
36	and rapidly growing team	1	0.29%
37	growing team driven by	1	0.29%
38	and their families read	1	0.29%
39	advance this exciting area	1	0.29%
40	therapeutics to host 2nd	1	0.29%